Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update.
Virgo KS, Rumble RB, de Wit R, Mendelson DS, Smith TJ, Taplin ME, Wade JL 3rd, Bennett CL, Scher HI, Nguyen PL, Gleave M, Morgan SC, Loblaw A, Sachdev S, Graham DL, Vapiwala N, Sion AM, Simons VH, Talcott J. Virgo KS, et al. Among authors: loblaw a. J Clin Oncol. 2021 Apr 10;39(11):1274-1305. doi: 10.1200/JCO.20.03256. Epub 2021 Jan 26. J Clin Oncol. 2021. PMID: 33497248
Intensity-modulated radiotherapy in the treatment of prostate cancer.
Bauman G, Rumble RB, Chen J, Loblaw A, Warde P; Members of the IMRT Indications Expert Panel. Bauman G, et al. Among authors: loblaw a. Clin Oncol (R Coll Radiol). 2012 Sep;24(7):461-73. doi: 10.1016/j.clon.2012.05.002. Epub 2012 Jun 4. Clin Oncol (R Coll Radiol). 2012. PMID: 22673744 Review.
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM, Woo HH, Bassett JK, Bowe SJ, D'Este C, Frydenberg M, King M, Ledwich L, Loblaw A, Malone S, Millar J, Milne R, Smith RG, Spry N, Stockler M, Syme RA, Tai KH, Turner S. Duchesne GM, et al. Among authors: loblaw a. Lancet Oncol. 2016 Jun;17(6):727-737. doi: 10.1016/S1470-2045(16)00107-8. Epub 2016 May 4. Lancet Oncol. 2016. PMID: 27155740 Clinical Trial.
Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy.
Mendez LC, Ravi A, Chung H, Tseng CL, Wronski M, Paudel M, McGuffin M, Cheung P, Loblaw A, Morton G. Mendez LC, et al. Among authors: loblaw a. Brachytherapy. 2018 Mar-Apr;17(2):291-297. doi: 10.1016/j.brachy.2017.10.001. Epub 2017 Nov 11. Brachytherapy. 2018. PMID: 29137956
Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial.
Murgic J, Morton G, Loblaw A, D'Alimonte L, Ravi A, Wronski M, Davidson M, Haider M, Commisso K, Zhang L, Chung HT. Murgic J, et al. Among authors: loblaw a. Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):561-567. doi: 10.1016/j.ijrobp.2018.06.039. Epub 2018 Jul 2. Int J Radiat Oncol Biol Phys. 2018. PMID: 30244878 Clinical Trial.
201 results